产品
编 号：F761082
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 881191-44-2
产品详情
生物活性：
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
体内研究：
Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice.Animal Model:BALB/c-huCD3e mice carrying the human CD3e chain
Dosage:100 μg/mouse
Administration:Intravenous injection, once
Result:Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.
体外研究：
Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days.Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction.
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
体内研究：
Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice.Animal Model:BALB/c-huCD3e mice carrying the human CD3e chain
Dosage:100 μg/mouse
Administration:Intravenous injection, once
Result:Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.
体外研究：
Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days.Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备